PureTech Health PLC

PRTC

Company Profile

  • Business description

    PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

  • Contact

    6 Tide Street
    Suite 400
    BostonMA02210
    USA

    T: +1 617 482-2333

    E: [email protected]

    https://www.puretechhealth.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    56

Stocks News & Analysis

stocks

Why stocks sometimes fall for no obvious reason

How the private markets impact all equity investors.
stocks

Poor organic growth obscured by acquisition for ASX listed share

Sales dropped by 2% without impact of acquisition.
stocks

Nvidia dominance continues

Our view on the latest earnings report.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,877.2015.00-0.17%
CAC 408,115.7529.750.37%
DAX 4024,888.56281.791.15%
Dow JONES (US)50,708.20422.540.84%
FTSE 10010,466.2622.790.22%
HKSE25,606.03219.510.86%
NASDAQ26,410.79117.690.45%
Nikkei 22563,339.071,654.932.68%
NZX 50 Index12,991.31113.240.88%
S&P 5007,489.6143.890.59%
S&P/ASX 2008,657.0015.10-0.17%
SSE Composite Index4,112.9035.620.87%

Market Movers